Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration-Reference-Cited by-同舟云学术

Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration

Published:2019-01-02 Issue:5 Volume:24 Page:546-553
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Shigeta Keisuke,Kosaka Takeo^ORCID,Hongo Hiroshi,Yanai Yoshinori,Matsumoto Kazuhiro,Morita Shinya,Mizuno Ryuichi,Shinojima Toshiaki,Kikuchi Eiji,Oya Mototsugu

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/content/pdf/10.1007/s10147-018-01388-5.pdf

Reference25 articles.

1. Heidenreich A, Bastian PJ, Bellmunt J et al (2014) EAU guidelines on prostate cancer. Part I: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65:124–137

2. Heidenreich A, Bastian PJ, Bellmunt J et al (2014) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65:467–479

3. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

4. Ryan CJ, Smith MR, de Bono JS et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138–148

5. Beer TM, Armstrong AJ, Rathkopf DE et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424–433

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Curcumin blunts epithelial-mesenchymal transition to alleviate invasion and metastasis of prostate cancer through the JARID1D demethylation;Cancer Cell International;2024-09-01

2. The m6A regulators in prostate cancer: molecular basis and clinical perspective;Frontiers in Pharmacology;2024-08-29

3. An 18-Gene Algorithm urine test for predicting prostate cancer metastasis and castration- resistance;2023-10-13

4. The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer;International Journal of Clinical Oncology;2022-12-29

5. Functional analysis of GCNT3 for cell migration and EMT of castration-resistant prostate cancer cells;Glycobiology;2022-07-09